Why Algernon believes it is the Janis Joplin of psychedelic medicine companies

The Canadian company Algernon (CSE:AGN; Frankfurt:AGW0; OTCQB:AGNPF) is the headline sponsor for the Wonderland psychedelic medicine conference held in Miami from November 3 to 5. Algernon CEO Chris Moreau expects the decision to prominently back the event will raise the company’s profile. “We view Algernon as a Janis Joplin voice singing to a junior high crowd right now,” Moreau said. “We’re sort of undiscovered, but the parents in the audience think the music is fantastic. People are looking at each other in amazement, but it’s in the school gym.”

The Vancouver–based company has three drugs in its pipeline — ifenprodil and repirinast for inflammatory disorders and the psychedelic compound DMT for ischemic stroke rehabilitation.

In late October, the company announced a research alliance with Yale University to explore using DMT in a Phase 2 depression study.

In a recent interview, Moreau shared details on its DM…

Read more
  • 0

Why Algernon is investigating DMT in stroke rehabilitation

The clinical-stage company Algernon Pharmaceuticals (CSE:AGN; Frankfurt:AGW0; OTCQB: AGNPF) has received approval to run a Phase 1 clinical study of an IV formulation of AP-188.

The study will explore the drug candidate’s potential, a formulation of the classic psychedelic N,N-dimethyl tryptamine or DMT, to treat stroke patients in the Netherlands.

The Stichting Beoordeling Ethiek Biomedisch Onderzoek (“BEBO”), an independent medical research ethics committee, will manage the study.

Algernon decided to investigate the potential of DMT in human studies for ischemic stroke after reviewing data from independent studies demonstrating that DMT can mitigate tissue damage while promoting neurogenesis and neuroplasticity.

To learn more about Algernon’s plans to explore the potential of DMT as a therapy for ischemic stroke, we spoke with Christopher J. Moreau, the company’s CEO.

What led to your interest in DMT as a potent…
Read more
  • 0